Inhibikase Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(1) For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report, incorporated into this Item by reference.
(2) Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto. Those financial statement schedules required to be filed by Item 8 of this form, and by paragraph (b) below.
(3) The information required by this Item is set forth on the exhibit index of this Annual Report.
EXHIBIT INDEX
| Where Located | ||||||
|---|---|---|---|---|---|---|
| Exhibit Number | Description* | Form | File Number | Exhibit Number | Filing Date | Filed Herewith |
| 2.1†* | Agreement and Plan of Merger and Reorganization, dated February 21, 2025, by and among Inhibikase Therapeutics, Inc., Project IKT Merger Sub, Inc., CorHepta Pharmaceuticals, Inc. and Sellers’ Representative | 10-K | 001-39676 | 2.1 | 03/27/2025 | |
| 3.1 | Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc. | 8-K | 001-39676 | 3.1 | 12/29/2020 | |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc. | 8-K | 001-39676 | 3.1 | 06/29/2023 | |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Inhibikase Therapeutics, Inc. | 8-K | 001-39676 | 3.1 | 01/06/2025 | |
| 3.4 | Amended and Restated Bylaws of Inhibikase Therapeutics, Inc. | 8-K | 001-39676 | 3.2 | 12/29/2020 | |
| 4.1 | Specimen common stock Certificate of the Registrant | S-1 | 333-240036 | 4.1 | 07/23/2020 | |
| 4.2 | Form of Warrant to purchase common stock of the Registrant, issued to each of the members of the Scientific Advisory Board and the investor named in Schedule A thereto | S-1 | 333-240036 | 4.2 | 07/23/2020 | |
| 4.3 | Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated January 1, 2019 | S-1/A | 333-240036 | 4.4 | 09/15/2020 | |
| 4.4 | Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated March 31, 2020 | S-1 | 333-240036 | 4.5 | 07/23/2020 | |
| 4.5 | Form of Representative’s Warrant | S-1 | 333-240036 | 4.6 | 07/23/2020 | |
| 4.6 | Form of Late IPO Warrant | S-1 | 333-240036 | 4.7 | 07/23/2020 | |
| 4.7 | Form of Private Common Warrant | 8-K | 001-39676 | 4.2 | 01/26/2023 | |
| 4.8 | Form of PIPE Common Warrant | 8-K | 001-39676 | 4.4 | 01/26/2023 | |
| 4.9 | Form of Series B Warrant | 8-K | 001-39676 | 4.3 | 05/20/2024 | |
| 4.10 | Form of Warrant Amendment | 8-K | 001-39676 | 4.6 | 05/20/2024 | |
| 4.11 | Form of Pre-Funded Warrant | 8-K | 001-39676 | 4.1 | 10/10/2024 | |
| 4.12 | Form of Series A-1 Warrant | 8-K | 001-39676 | 4.2 | 10/10/2024 | |
| 4.13 | Form of Series B-1 Warrant | 8-K | 001-39676 | 4.3 | 10/10/2024 | |
| 4.14 | Form of Pre-Funded Warrant | 8-K | 001-39676 | 4.1 | 11/21/2025 | |
| 4.15 | Form of Amendment to Series A-1 Warrant | 8-K | 001-39676 | 4.2 | 11/21/2025 | |
| 4.16 | Form of Amendment to Series B-1 Warrant | 8-K | 001-39676 | 4.3 | 11/21/2025 | |
| 4.17 | Description of Securities of the Registrant | X | ||||
| 10.1 | Collaborative Research and Development Agreement, by and between Inhibikase Therapeutics, Inc. and Sphaera Pharma Pte. Ltd., dated February 29, 2012 | S-1 | 333-240036 | 10.2 | 07/23/2020 | |
| 10.2 | First Amendment to Collaborative Research and Development Agreement, by and between Inhibikase Therapeutics Inc. and Sphaera Pharma Pte. Ltd., dated October 5, 2012 | S-1 | 333-240036 | 10.3 | 07/23/2020 | |
| 10.3# | 2011 Equity Incentive Plan and forms of agreements thereunder | S-1 | 333-240036 | 10.4 | 07/23/2020 | |
| 10.4# | 2020 Equity Incentive Plan and forms of agreements thereunder | S-1/A | 333-240036 | 10.5 | 12/04/2020 | |
| 10.5# | Amendment No. 1 to Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan | S-8 | 333-284687 | 99.2 | 02/05/2025 | |
| 10.6# | Amendment No. 2 to Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan | S-8 | 333-284687 | 99.3 | 02/05/2025 | |
| 10.7# | Amendment No. 3 to Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan | 10-Q | 001-39676 | 10.1 | 08/14/2025 | |
| 10.8 | Form of Inhibikase Therapeutics, Inc. Directors and Officers Indemnification Agreement | S-1 | 333-240036 | 10.9 | 07/23/2020 | |
| 10.9 | Form of Consulting Agreement | S-1 | 333-240036 | 10.15 | 07/23/2020 | |
| 10.10 | Form of Stock Option Grant Notice and Award Agreement | 8-K | 001-39676 | 10.3 | 03/08/2022 | |
| 10.11 | Registration Rights Agreement, dated as of January 25, 2023 (PIPE) | 8-K | 001-39676 | 10.3 | 01/26/2023 | |
| 10.12# | Employment Agreement between Inhibikase Therapeutics, Inc. and Garth Lees-Rolfe, dated as of April 1, 2024 | S-1 | 333-278844 | 10.18 | 04/19/2024 | |
| 10.13 | Securities Purchase Agreement, dated as of May 20, 2024 | 8-K | 001-39676 | 10.1 | 05/20/2024 | |
| 10.14 | Placement Agency Agreement, dated as of May 20, 2024 | 8-K | 001-39676 | 10.2 | 05/20/2024 | |
| 10.15 | Inducement Letter, dated as of May 20, 2024 | 8-K | 001-39676 | 10.3 | 05/20/2024 | |
| 10.16 | Securities Purchase Agreement, dated as of October 9, 2024 | 8-K | 001-39676 | 10.1 | 10/10/2024 | |
| 10.17 | Form of Registration Rights Agreement | 8-K | 001-39676 | 10.2 | 10/10/2024 | |
| 10.18# | Form of Director Offer Letter | 8-K | 001-39676 | 10.4 | 10/10/2024 | |
| 10.19 | Settlement Agreement, dated as of September 30, 2024 | 8-K | 001-39676 | 10.5 | 10/10/2024 | |
| 10.20 | Consulting Agreement, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated February 13, 2025 | 10-K | 001-39676 | 10.27 | 03/27/2025 | |
| 10.21# | Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Mark Iwicki, dated February 14, 2025 | 10-K | 001-39676 | 10.28 | 03/27/2025 | |
| 10.22# | Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Christopher Cabell, dated February 21, 2025 | 10-K | 001-39676 | 10.29 | 03/27/2025 | |
| 10.23# | Employment Agreement, by and between Inhibikase Therapeutics, Inc. and David McIntyre, dated as of March 13, 2025 | 8-K | 001-39676 | 99.2 | 04/14/2025 | |
| 19.1 | Amended & Restated Insider Trading Policy | 10-K | 001-39676 | 19.1 | 03/27/2025 | |
| 21.1 | Subsidiaries of the Registrant | 10-K | 001-39676 | 21.1 | 03/27/2025 | |
| 23.1 | Consent of Independent Registered Public Accounting Firm. | X | ||||
| 24.1 · Power of Attorney (included on signature) · X | ||||||
|---|---|---|---|---|---|---|
| 31.1 · Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 · X | ||||||
| 31.2 · Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 · X | ||||||
| 32.1** · Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||||
| 32.2** · Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||||
| 97.1 | Compensation Clawback Policy | 10-K/A | 001-39676 | 97.1 | 4/25/2025 | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | ||||
(#) A contract, compensatory plan or arrangement to which a director or executive officer is a party or in which one or more directors or executive officers are eligible to participate.
(†) Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted attachment to the SEC on a confidential basis upon request.
(*) Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
(**) Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.